Lincolnshire Prescribing and Clinical Effectiveness Bulletin – Vol 14 No 4

July 2020

Optum in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust

This Bulletin details the decisions made at the PACEF meeting held on July 15th 2020.

Table of Contents

DRUG ASSESSMENT SUMMARY

Product	Summary	Decision
Leuprorelin acetate 3.75mg (Prostap SR DCS) & 11.25mg (Prostap 3 DCS)	**Introduction:** Leuprorelin acetate is now licensed for the treatment of breast cancer. It can be used as adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, in line with product license. The dose is either 3.73 mg administered as a single subcutaneous injection once a month or the higher strength 11.25mg administered as a single subcutaneous injection once every 3 months. Both formulations are provided as powder and solvent for prolonged release suspension for injection in Pre-filled syringe. Previously Goserelin was the only gonadorelin analogue (GnRH agonist) licensed for the treatment of breast cancer and was included on the Lincolnshire formulary solely for this indication. Now both Leuprorelin and Triptorelin are licensed for the treatment of breast cancer. ULHT specialists have requested that all three gonadorelin analogues are included on the formulary for this indication. **Further relevant information:** The frequency of treatment of the GnRH agonists varies with Goserelin acetate 3.6mg implant to be administered subcutaneously once every 28 days whereas leuprorelin acetate 3.75mg is given monthly by subcutaneous injection and triptorelin (Decapeptyl S.R 3mg) once every four weeks, by intramuscular injection. The 11.25mg strength of leuprorelin is the only formulation licensed as a 3 monthly treatment, and this has the advantage of reduced frequency of injections which may be preferable for both the patient and the health care professional providing the treatment. The annual cost of using each of the 3 products are very similar.	Approved for inclusion on the formulary as AMBER 2, for the treatment of breast cancer within product license.
Triptorelin acetate (Decapeptyl SR 3mg)	**Introduction:** Triptorelin acetate (Decapeptyl S.R 3mg) product license has been extended to cover the treatment of breast cancer. It can be used as adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, in line with product license. The dose is 3mg administered by intramuscular injection once every 4 weeks (28 days). **Further relevant information:** PACEF approved the review of existing formulary advice to include use of triptorelin for the treatment of breast cancer.	Approved for inclusion on the formulary as AMBER 2, for the treatment of breast cancer within product license.

Product	Summary	Decision
Timolol 0.5%w/v gel forming eye drops solution. (Timoptol LA) 0.5%	**Introduction:** Timoptol LA 0.5% gel forming eye drops are licensed for the reduction of elevated intra-ocular pressure in various eye conditions. PACEF had received a request from Cambridgeshire and Peterborough hospitals to consider the unlicensed use of this product for the treatment of small superficial lesions in the management of infantile haemangioma in children and for those where systemic propranolol therapy is deemed inappropriate. Cambridgeshire and Peterborough Joint Prescribing Group had considered the supporting evidence and recommended the unlicensed use of this product, in line with local treatment guidelines. **Further relevant information:** Research has shown that the use of timolol 0.5% in the form of the long-acting eye gel is as effective as oral propranolol for the treatment of small lesions. The number of adverse events seen in studies of topical timolol for infantile haemangiomas is low. Topical treatment is well tolerated with a low incidence of side effects. Topical treatment would not be suitable for treatment of multiple lesions. It is also less effective in deeper lesions and unsuitable for use in e.g. ulcerated lesions. PACEF approved the use of timolol 0.5% gel forming eye drops for inclusion onto the Lincolnshire formulary, as AMBER 2. All treatments will be initiated by or on the request of a specialist and in line with treatment guidelines.	Approved for inclusion on the formulary as AMBER 2.

Produced by:
Medicines Management & Optimisation Service
Optum Health Systems Support

July 2020

T 020 7121 0560 I E info@optum.co.uk I **optum.co.uk**
10th Floor, 5 Merchant Square, Paddington, London, W2 1AS